Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afamelanotide Monotherapy for Facial Vitiligo
NCT05210582Phase 2Unknown
- Sponsor
- Clinuvel Pharmaceuticals
- Start
- Oct 2022
- Primary completion
- Apr 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Afamelanotide in Vitiligo, sponsored by Clinuvel Pharmaceuticals. Status: unknown.
02
Drugs
Afamelanotide
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NCT05210582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05210582.